Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico.

Autor: Bernal Luna Y; Instituto Mexicano del Seguro Social Hospital General Regional 251, Metepec, Mexico.; Universidad Autónoma del Estado de México, Facultad de Medicina, Toluca, Mexico., Esquivel Loza A; Instituto Mexicano del Seguro Social Hospital General Regional 251, Metepec, Mexico., Garduño García JJ; Instituto Mexicano del Seguro Social Hospital General Regional 251, Metepec, Mexico.; Universidad Autónoma del Estado de México, Facultad de Medicina, Toluca, Mexico.
Jazyk: angličtina
Zdroj: Advances in virology [Adv Virol] 2022 Dec 06; Vol. 2022, pp. 6880405. Date of Electronic Publication: 2022 Dec 06 (Print Publication: 2022).
DOI: 10.1155/2022/6880405
Abstrakt: Introduction: COVID-19 has been associated with the overactivation of the immune system; interleukin-6 (IL-6) seems to have a key role, which made its moderation to be proposed as a therapeutic blank. Tocilizumab has been used as part of treatments to modulate the immune response to infections caused by COVID-19. Material and Methods . An observational, descriptive, retrospective, and transversal study was carried out in patients diagnosed with moderate-severe COVID-19 who were hospitalized in the 251 General Regional Hospital from March to December 2020.
Results: A review of 700 files corresponding to hospitalized patients was carried out, and a sample of 70 patients who met the inclusion criteria proposed for this protocol was obtained. Among the comorbidities associated with the disease, it was found that hypertensive patients have a higher mortality rate: 62% died and so did 59% of those who needed invasive respiratory support. As regards admission tests, statistical significance was found for the figures of leukocytes, neutrophils, glomerular filtration rate, and PCR.
Conclusion: The use of this drug benefits mainly young nonhypertensive patients with a moderate disease and preserved renal functions with no need for invasive respiratory support, regardless of other comorbidities.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2022 Yessica Bernal Luna et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje